A single-tube multiplex method for monitoring mutations in cysteine 481 of Bruton Tyrosine Kinase (BTK) gene in chronic lymphocytic leukemia patients treated with ibrutinib
- 4 March 2021
- journal article
- letter
- Published by Taylor & Francis Ltd in Leukemia & Lymphoma
- Vol. 62 (8), 2018-2021
- https://doi.org/10.1080/10428194.2021.1894643
Abstract
The irreversible Bruton tyrosine kinase (BTK) inhibitor ibrutinib has changed the therapeutic landscape of patients affected by chronic lymphocytic leukemia (CLL), leading to high clinical response...Funding Information
- Associazione Italiana per la Ricerca sul Cancro
- Fondazione Cariplo [
- Fondazione Umberto Veronesi
This publication has 13 references indexed in Scilit:
- Mechanisms of ibrutinib resistance in chronic lymphocytic leukemia and alternative treatment strategiesExpert Review of Hematology, 2020
- Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor–resistant chronic lymphocytic leukemia with disease progression and Richter transformationCancer, 2018
- BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic LeukemiaJournal of Clinical Oncology, 2017
- Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemiaBlood, 2017
- Using high-sensitivity sequencing for the detection of mutations in BTK and PLCγ2 genes in cellular and cell-free DNA and correlation with progression in patients treated with BTK inhibitorsOncotarget, 2017
- Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre studyThe Lancet Oncology, 2016
- Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic LeukemiaThe New England Journal of Medicine, 2016
- Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic LeukemiaThe New England Journal of Medicine, 2015
- Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid LeukemiaThe New England Journal of Medicine, 2014
- Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor IbrutinibThe New England Journal of Medicine, 2014